Canadian CANNAINVESTOR Magazine September 2018 | Page 224

Lexaria Bioscience Corp. CSE:LXX | OTCQX:LXRP Lexaria Bioscience has developed a new disruptive drug delivery platform: DehydraTECH™ The Company’s patented technology changes the way Active Pharmaceutical Ingredients (“APIs”) enter the body orally: 1) 2) 3) 4) Masks unwanted tastes – eliminates the need for sugar-filled edibles. Reduces time of onset – effects are felt within 15-20 min vs. 60-120 min. Avoids first-pass liver metabolism – mitigating unwanted side effects. Increases bio-absorption by 5-10X - to equate absorption by inhalational delivery. The Company’s DehydraTECH™ technology is patent-protected for multiple APIs: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, Nicotine, Fat soluble vitamins. Business Model: 1) Out-license (royalty) the technology to third-party partners / distributors. Range: 5-10% of gross sales. 2) Product Sales - Lexaria sells hemp oil CBD ( cannabidiol ) products. ViPova™ branded premium teas deliver CBD in several flavors. TurboCBD TM hemp oil capsules are formulated with Ginseng & Ginkgo for enhanced focus and memory. Growing Patent Portfolio – 20+ patent applications filed in US, International (under the Patent Cooperation Treaty), and national filings in 44 countries. Patents include both method and composition of matter claims. Patents issued in USA, Australia: “Food and beverage compositions infused with lipophilic active agents and methods of use thereof”. Research Agreements with National Research Council and other laboratories to investigate opportunities associated with bioavailability enhancement of lipophilic active ingredient, and research on additional DehydraTECH™ applications. 2018 research program showed DehydraTECH™ delivered 225% increase in penetration of CBD topical skin creams. In-vivo (in- animal) lab tests are also pending for nicotine in edible formats. Nicotine edibles do not currently exist due to nicotine’s inability to pass through the human GI tract without irritation. DehydraTECH™ may offer a disruptive alternative to this $770B market, which is aggressively pursuing cigarette alternatives. Key Executives: Chris Bunka - Chairman & CEO. Serial entrepreneur, extensive experience in the capital markets, corporate governance, M&A and finance. Stock Information: Trading symbol: CSE:LXX, OTCQB:LXRP Shares o/s: 72m, (f/d: 80m) Mgmt & Insiders: 15m (21%) Recent price: C$1.97 / US$1.57 John Docherty, M.Sc. - Director & President. 20 yr. senior executive in the pharmaceutical and bioscience M.Sc. in pharmacology and B.Sc. in toxicology from the University of Toronto. Mr. Ted McKechnie – Director. Senior entrepreneurial executive with extensive senior management & board experience in the consumer goods industry in National and Retail brands. Former President and COO of Maple Leaf Foods. For more information, contact Alex Blanchard, Communications Manager: [phone], Email: [email protected] This Fact Sheet is provided by Lexaria Bioscience Corporation as a convenience for potential investors. More details about the business and its risks can be found in the Company’s press releases and filings with the U.S. Securities and Exchange Commission or the Canadian Securities Administrators. This Fact Sheet contains forward-looking statements and actual results may differ materially from such statements. www.lexariabioscience.com May 2018